You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1250 Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: a case-control study with translational correlates

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immunotherapy Toxicities
1250 Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: a case-control study with translational correlates

Authors

  • Steph A Pang Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Manuel Flores Molina Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Paméla Thébault Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Hsiang Chou Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Christophe Goncalves Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Paulo Nunes Filho Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Sabin Filimon McGill University Health Center, Division of Cardiology, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Tingting Chen Meakins-Christie Laboratories, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Lucas A Salas Department of Epidemiology, Geisel School of Medicine at Dartmouth, Dartmouth Cancer Center, Lebanon, NH, USA PubMed articlesGoogle scholar articles
  • Khashayar Esfahani Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Caroline M Michel Sir Mortimer B. Davis Jewish General Hospital, Division of Cardiology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Jun Ding Meakins-Christie Laboratories, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Sonia VDel Rincon Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Marie Hudson Lady Davis Institute and Sir Mortimer B. Davis Jewish General Hospital, Division of Rheumatology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Réjean Lapointe Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada PubMed articlesGoogle scholar articles
  • Wilson H Miller Lady Davis Institute and Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada PubMed articlesGoogle scholar articles

Citation

Pang SA, Molina MF, Thébault P, et al
1250 Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: a case-control study with translational correlates
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1250

Publication history

  • First published November 2, 2023.
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.